Work

Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study

Year: 2017

Type: article

Study design: Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(17)30763-5

Authors: Huiping Li, Qingyuan Zhang, Wei Li, Shusen Wang, Ning Liao, Peng Shen, Bin Shao, Wenhui Zhao, Wan Sun, Ping Yan, Diane Wang, Vince (Bai) Li, Carlos Linn, Haihong Shi, Melissa O'Gorman, Binghe Xu

Institutions: Peking University Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, First Hospital of Jilin University, Sun Yat-sen University Cancer Center, Guangdong General Hospital, First Affiliated Hospital Zhejiang University, Zhejiang University, Pfizer (United States), Pfizer (China), Chinese Academy of Medical Sciences & Peking Union Medical College

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2756972088

FWCI: 0.262

Cites:

Cited by: 5

Related to: 10